 |
Inside Neotropix
Many viruses have evolved, over billions of years,
to do exactly what is needed to create effective
cancer therapies: kill tumor cells but not
normal cells. Neotropix works to harness viruses'
natural infectious and replicative properties
to treat cancer and other diseases that are
resistant to available therapeutic methods.
Neotropix
began a Phase IA-II Clinical Trial on our first
cancer drug candidate in May, 2006.
We urge you to explore Neotropix and learn about
our work as a leading biotechnology company in
the emerging field of virotherapy.
Neotropix is in the forefront of research and treatment in specific areas such as carcinoid, neuoendocrine, rhabdomyosarcoma, neuroblastoma, retinoblastoma, medulloblastoma, retinoblastoma, rhabdoid, glioblastoma and wilms. |
|
Product Spotlight
NTX-010: NTX-010
is a novel virus that specifically attacks and
kills small cell lung cancer cells and certain
other neuroendocrine cancers.
Read
More.
|
|
Research Areas
Specific areas of research and treatment are in carcinoid, neuoendocrine, rhabdomyosarcoma, neuroblastoma, retinoblastoma, medulloblastoma, retinoblastoma, rhabdoid, glioblastoma and wilms |
